Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection.

@article{Vazquez2007SafetyAE,
  title={Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection.},
  author={Jose Alberto Vazquez and Daniel J. Skiest and Herv{\'e} Tissot-Dupont and Jeffrey L. Lennox and Navdeep Boparai and Randi Isaacs},
  journal={HIV clinical trials},
  year={2007},
  volume={8 2},
  pages={86-97}
}
PURPOSE To evaluate safety and efficacy of long-term posaconazole in HIV-infected patients with azole-refractory oropharyngeal candidiasis and/or esophageal candidiasis. METHOD In this noncomparative, open-label study, participants received oral posaconazole 400 mg twice daily (bid) for 3 months. Enrolled patients (N = 100) included 60 from a previous 1-month acute study of posaconazole and 40 posaconazole-naïve participants. Participants with a clinical response could be followed untreated… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Posaconazole: An Update of Its Clinical Use

View 16 Excerpts
Highly Influenced

ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases • 2012
View 2 Excerpts

Similar Papers

Loading similar papers…